Metastatic Prostate Cancer Epidemiology

• Prostate cancer is the third most prevalent type of cancer in the US and the fourth most common worldwide.
• Prostate cancer is most frequently diagnosed among men aged 65–74 years; the median age at diagnosis is 66 years.
• Around 45% of the patients had mCSPC/mHSPC, and around 55% had mCRPC. 
• Studies show a continued increase in the incidence of distant-stage prostate cancer in the United States. The percentage of distant-stage prostate cancer increased from 4% in 2003 to 8% in 2017
• The global burden of prostate cancer continues to increase due to population aging, improved screening practices, and enhanced diagnostic technologies. Recent published estimates indicate that more than 1.4–1.5 million new prostate cancer cases are diagnosed globally each year, making it the second most frequently diagnosed cancer in men worldwide. Incidence rates are rising particularly in older men and in countries with widespread PSA-based screening programs.

Metastatic Prostate Cancer Epidemiology Forecast in the 7MM

• 2025 Prevalent Cases of Metastatic Prostate Cancer : ~315,000
• Prostate Cancer Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Metastatic Prostate Cancer Epidemiology Forecast 2036’ report delivers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Metastatic Prostate Cancer Understanding and Diagnosis Algorithm

Metastatic Prostate Cancer Overview and Diagnosis

Metastatic prostate cancer is an advanced stage of prostate malignancy in which cancer cells spread beyond the prostate gland to distant sites, most commonly the bone, lymph nodes, liver, and lungs. It typically progresses from localized disease to metastatic hormone-sensitive prostate cancer (mHSPC) and eventually to metastatic castration-resistant prostate cancer (mCRPC). Diagnosis is based on a combination of PSA testing, imaging, and histopathology. Elevated prostate-specific antigen (PSA) levels often initiate further evaluation, although PSA alone is not diagnostic of metastatic disease. 

Further details are provided in the report.

Metastatic Prostate Cancer Diagnosis

Diagnosis is based on a combination of PSA testing, imaging, and histopathology. Elevated prostate-specific antigen (PSA) levels often initiate further evaluation, although PSA alone is not diagnostic of metastatic disease. Imaging modalities such as bone scans, CT/MRI, and PSMA PET/CT are central to detecting and staging metastatic spread, with PSMA PET/CT offering superior sensitivity. Definitive diagnosis is confirmed via prostate biopsy, while metastatic lesions may be biopsied in select cases for further characterization. Disease classification into mHSPC or mCRPC is determined by response to ADT and testosterone suppression levels, which directly guides treatment strategy.

Further details are provided in the report.

Metastatic Prostate Cancer Epidemiology

Key Findings from Metastatic Prostate Cancer Epidemiological Analysis and Forecast 

• According to DelveInsight’s estimates, in 2025, the total number of prevalent cases of metastatic prostate cancer in the 7MM were ~315,000.
• Based on DelveInsight's estimates in 2025, the US had ~3,864,000 prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2026−2036). 
• The five-year prevalent cases of prostate cancer in the US was approximately ~1,157,000 in 2025.
• In 2025, in the US, the total cases of mCSPC were approximately ~72,500.
• According to the SEER, prostate cancer is most frequently diagnosed among men aged 65–74 years; the median age at diagnosis is 66 years. The most number of cases was found in people aged between 65 and 74 years, followed by 55–64 years and 75–84 years. 

Scope of the Report

• The report covers a segment of a descriptive overview of hand eczema, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Metastatic Prostate Cancer Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of hand eczema? What will be the growth opportunities across the 7MM concerning the patient population with hand eczema?
• What is the historical and forecasted hand eczema patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.